Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Smith & Nephew plc (SNN) Price & Performance

Roundhill NVDA WeeklyPay ETFTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Roundhill NVDA WeeklyPay ETF vs Smith & Nephew plc — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.16, while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Smith & Nephew plc pays a 2.85% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Roundhill NVDA WeeklyPay ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.

NVDWSNN
Sector
Income / Options OverlayHealth
52-Week High
$52.33$38.53
52-Week Low
$31.88$27.80
Market Cap
$11.63B
Enterprise Value
$14.66B
Dividend Yield
2.85%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Roundhill NVDA WeeklyPay ETF

NVDW (Roundhill NVDA WeeklyPay ETF) trades at $37.60, down 3.22% with a bullish technical signal from moving averages. The ETF provides leveraged exposure to Nvidia with weekly dividend payments, though key valuation ratios remain unavailable. Recent news highlights its high-yield income strategy tied to NVDA's performance, with payouts fluctuating based on underlying stock volatility.

The outlook depends heavily on Nvidia's continued earnings strength and AI market momentum. Key risks include leverage amplification during NVDA downturns and variable dividend sustainability. Investors seeking weekly income from tech exposure may find value, but must monitor NAV erosion risks amid sector volatility.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.

Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.

Returns comparison

Trailing returns across standard periods

About Roundhill NVDA WeeklyPay ETF

NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.

Read more on NVDW

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN